Neuroaxonal Dystrophies: Clinical Trials

20 trials for Neuroaxonal Dystrophies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 3 recruiting, 3 unknown, 2 terminated. 6 Not applicable, 4 Phase 3, 1 Phase 2, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable6Completed 3, Not yet recruiting 1, Recruiting 1, Unknown 1
Phase 34Completed 2, Active not recruiting 1, Terminated 1
Phase 21Active not recruiting 1
Phase 41Terminated 1

Follow Neuroaxonal Dystrophies: new trials by email Literature Review of Neuroaxonal Dystrophies trials Research Report on Neuroaxonal Dystrophies

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Brain Iron in Beta-Propeller Protein Associated Neurodegeneration (BPAN)
Standardized brain MRI including specific sequences usable for Quantitative Susceptibility Mapping (QSM) - Neurodegeneration With Brain Iron Accumulation (NBIA), Iron Metabolism Disorders
Not applicableNot yet recruitingUniversity Hospital, Bordeaux32026-12-012026-10-09
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
Observation - Neurodegenerative Diseases, Parkinson Disease
RecruitingCasa di Cura San Raffaele Cassino6002024-09-092026-09-02
Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.
Dematerialized Personalized Care Plan (ePCP) - Sarcoma Metastatic, Locally Advanced Soft Tissue Sarcoma
Not applicableRecruitingCentre Oscar Lambret3772024-05-292026-03-18
Functional Tests to Resolve Unsolved Rare Diseases. Rares.
Ex-vivo approach concerning 25 patients, In-vitro approach concerning 25 patients - Intellectual Disability, Rubinstein-Taybi Syndrome
Not applicableUnknownUniversity Hospital, Bordeaux502023-01-302024-02-21
European Registry on Rare Neurological Diseases
Data set as defined by the ERN Research Workgroup of the European Commission - Rare Diseases
UnknownUniversity Hospital Tuebingen50002021-10-012021-09-29
Occupational Therapy and Cognitive Challenges After Brain Injury
The Perceive, Recall, Plan and Perform System of Intervention - Brain Injuries, Cognitive Impairment
Not applicableCompletedNorwegian University of Science and Technology62021-04-282024-12-05
CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN)
CoA-Z, Placebo - Pantothenate Kinase-Associated Neurodegeneration
Not applicableCompletedOregon Health and Science University772019-12-042025-10-29
A Natural History Study of Infantile Neuroaxonal Dystrophy
Neuroaxonal Dystrophy, Infantile
CompletedBiojiva LLC432019-06-172022-04-08
Desipramine in Infantile Neuroaxonal Dystrophy (INAD).
Desipramine - Infantile Neuroaxonal Dystrophy
Phase 4TerminatedDuke University42019-01-142020-10-14
A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy
RT001 - Infantile Neuroaxonal Dystrophy
Phase 2 / Phase 3Active not recruitingBiojiva LLC192018-11-052021-10-14
Natural History of Infantile Neuroaxonal Dystrophy
Infantile Neuroaxonal Dystrophy, INAD
CompletedBiojiva LLC132018-07-302020-06-29
Testing of NBIA Genes: Analysis of Genetic Heterogeneity and Validation of Mitochondrial Markers for Assessing Causality of Sequence Variants.
Establishment of mitochondrial markers, Sequencing tests - Neurodegeneration With Brain Iron Accumulation (NBIA)
CompletedUniversity Hospital, Bordeaux702018-01-042022-11-14
Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants
Fosmetpantotenate, Placebo - Pantothenate Kinase-Associated Neurodegeneration
Phase 3TerminatedTravere Therapeutics, Inc.842017-07-172021-01-26
NBIAready: Online Collection of Natural History Patient-reported Outcome Measures
Neurodegeneration With Brain Iron Accumulation (NBIA)
UnknownSusan J. Hayflick3002015-04-012020-10-08
Patient and Provider Initiated Survivorship Care Planning
'My Care Plan', 'Survivorship Care Plan Builder' - Cancer
Not applicableCompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins412015-02-012016-04-21
Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration
Deferiprone oral solution - Pantothenate Kinase-Associated Neurodegeneration
Phase 3CompletedApoPharma682014-06-012020-08-25
Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN)
Pantothenate Kinase-associated Neurodegeneration (PKAN)
CompletedSusan J. Hayflick102013-04-012018-05-29
Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)
Deferiprone oral solution, Placebo - Pantothenate Kinase-Associated Neurodegeneration
Phase 3CompletedApoPharma892012-12-132019-07-05
TIRCON International NBIA Registry
Neurodegeneration With Brain Iron Accumulation (NBIA), Pantothenate Kinase-associated Neurodegeneration (PKAN)
RecruitingLMU Klinikum20002012-06-142025-06-05
Compassionate Use of Deferiprone in Patients With PKAN
Deferiprone - Pantothenate Kinase-Associated Neurodegeneration
No longer availableChiesi Canada Corp2022-11-14

Narrower conditions

Pantothenate Kinase-Associated Neurodegeneration (13)  ·  Cognitive Dysfunction (2)  ·  Albinism (1)  ·  Alzheimer Disease (1)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Ataxia (1)  ·  Brain Diseases (1)  ·  Brain Injuries (1)  ·  Chorea (1)  ·  Corticobasal Degeneration (1)  ·  Cystic Fibrosis (1)  ·  Dementia (1)  ·  Dystonia (1)  ·  Familial apoceruloplasmin deficiency (1)

Broader conditions

Central Nervous System Diseases (20)  ·  Nervous System Diseases (20)  ·  Brain Diseases (19)  ·  Basal Ganglia Diseases (13)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13)  ·  Genetic Diseases, Inborn (13)  ·  Heredodegenerative Disorders, Nervous System (13)  ·  Movement Disorders (12)  ·  Neurodegenerative Diseases (12)  ·  Mental Disorders (4)  ·  Metabolic Diseases (4)  ·  Nutritional and Metabolic Diseases (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Cognition Disorders (3)

Interventions

Deferiprone (3)  ·  Isoflurophate (2)  ·  Desipramine (1)  ·  Long Interspersed Nucleotide Elements (1)  ·  Observation (1)  ·  RT001 (1)  ·  fosmetpantotenate (1)

Sponsors

Biojiva LLC (3)  ·  University Hospital, Bordeaux (3)  ·  ApoPharma (2)  ·  Susan J. Hayflick (2)  ·  Casa di Cura San Raffaele Cassino (1)  ·  Centre Oscar Lambret (1)  ·  Chiesi Canada Corp (1)  ·  Duke University (1)  ·  LMU Klinikum (1)  ·  Norwegian University of Science and Technology (1)  ·  Oregon Health and Science University (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)  ·  Travere Therapeutics, Inc. (1)  ·  University Hospital Tuebingen (1)

Countries

United States (10)  ·  France (5)  ·  Italy (5)  ·  Germany (4)  ·  Canada (2)  ·  Czechia (2)  ·  Norway (2)  ·  Poland (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  China (1)  ·  Egypt (1)  ·  India (1)  ·  Netherlands (1)  ·  Saudi Arabia (1)

Top investigators

Peter Milner, MD (3)  ·  Susan J Hayflick, MD (3)  ·  Thomas Klopstock, MD (3)  ·  Elliott Vichinsky, MD (2)  ·  Fernando Tricta, MD (1)  ·  Heidi Vifladt (1)  ·  Katherine C Smith, Ph.D. (1)  ·  Nardo Nardocci, MD (1)  ·  Patrick Chinnery, MD (1)  ·  Penelope Hogarth, M.D. (1)  ·  Thomas Klopstock, Prof. Dr. (1)

Results publications

PMID 28410187, PMID 31055958, PMID 31202468, PMID 36198473, PMID 37380207, PMID 37605305, PMID 39744963, PMID 41270188

NIH funding

R01HD097328 (1)